GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming […]
GigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols. Read the full story from Endpoints: An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse […]
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from immune repertoires, today announced that it has been awarded a $1.37 million Phase II grant from the National Cancer Institute (NCI) through the NIH Small Business Innovation Research (SBIR) program. The grant supports discovery and development […]
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in […]
GigaGen Inc., a biotechnology company with patented technology for discovery of T cell receptor (TCR) and antibody therapeutics from human immune repertoires, today announced a collaboration with Cellular Therapeutics Limited (CTL) to investigate TCR sequences in Tumor Infiltrating Lymphocytes (TIL) for therapeutic potential. CTL, based in Manchester, England, is an immuno-oncology company specializing in the […]
GigaGen’s CEO, Dave Johnson, PhD, won the Best E-Poster Award for his presentation on “Manufacturing and Preclinical Validation of Recombinant Intravenous Immunoglobulin for Primary Immunodeficiency” in the Immunoglobulin and Immunomodulatory Therapy session on September 23, 2016 at the 17th biennial meeting of the European Society for Immunodeficiencies (“ESID”) in Barcelona, Spain. For details of the […]
GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has been awarded a $1.5 million Phase II grant from the National Institutes of Health (NIH). The Phase II grant was awarded through the NIH Small Business Innovation Research (SBIR) program in from the National Institute […]
GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is […]
GigaGen’s development of the world’s first synthetic immune system was covered recently in the Biospace.com story Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies. According to the article, “The development of therapeutics that harness the body’s immune system has exploded in popularity among biotech companies with many investing heavily in research and […]
GigaGen Inc., a world leader in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has achieved all of the technical goals for four Phase I grants from the National Institutes of Health (NIH). The Phase I grants were awarded through the NIH Small Business Innovation Research (SBIR) program in 2015 […]
The potential of GigaGen’s single cell sequencing and expression platform to revolutionize immunotherapy drug development and target discovery was highlighted in the recent Genome Web story Expanding Single-Cell Technology, GigaGen Moves Forward in Drug Development Market. According to the article: “Single-cell analysis firm GigaGen has made a sharp turn in its business plans over […]
GigaGen Studies Published in Peer-Reviewed Journal mAbs Validate Its Novel Monoclonal Antibody Discovery Approach in Mouse and Human Antibody Repertoires
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of preclinical data validating its Surge™ discovery platform to rapidly interrogate and screen mouse and human antibody repertoires. The findings appear in two separate studies published online in the peer-reviewed scientific journal mAbs and will be available in print in the upcoming […]
GigaGen closes $50M deal with Grifols
GigaGen has received $35 million in investment funding and $15 million licensing fee payment from Grifols. Read the full story from Endpoints: An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business
GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse […]
GigaGen Announces $1.37M National Cancer Institute (NCI) Grant Award for Discovery and Development of New Oncology Therapies
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from immune repertoires, today announced that it has been awarded a $1.37 million Phase II grant from the National Cancer Institute (NCI) through the NIH Small Business Innovation Research (SBIR) program. The grant supports discovery and development […]
GigaGen CEO Dave Johnson on Biotech Nation Radio – Ep. 16-41
Listen to Moira Gunn’s interview with Dave Johnson, PhD, CEO of GigaGen on “Creating a Synthetic Immune System” on Biotech Nation Radio.
GigaGen to Present on Copying and Mining Immune Systems for Drug Discovery at the LakePharma Protein Engineering Symposium
GigaGen Inc., a biopharmaceutical company with patented technology for discovery of T cell receptor (TCR) and antibody drugs from human and mouse immune repertoires, today announced that Dave Johnson, Ph.D., CEO of GigaGen, will present a research and development update at the 2016 LakePharma Protein Engineering Symposium at the South San Francisco Conference Center in […]
GigaGen and Cellular Therapeutics Ltd Sign Collaboration for Novel TCR Discovery Directly from Patient’s T cells
GigaGen Inc., a biotechnology company with patented technology for discovery of T cell receptor (TCR) and antibody therapeutics from human immune repertoires, today announced a collaboration with Cellular Therapeutics Limited (CTL) to investigate TCR sequences in Tumor Infiltrating Lymphocytes (TIL) for therapeutic potential. CTL, based in Manchester, England, is an immuno-oncology company specializing in the […]
GigaGen Wins Best E-Poster Award at ESID for Presentation of Preclinical Data for Recombinant Intravenous Immunoglobulin (IVIG)
GigaGen’s CEO, Dave Johnson, PhD, won the Best E-Poster Award for his presentation on “Manufacturing and Preclinical Validation of Recombinant Intravenous Immunoglobulin for Primary Immunodeficiency” in the Immunoglobulin and Immunomodulatory Therapy session on September 23, 2016 at the 17th biennial meeting of the European Society for Immunodeficiencies (“ESID”) in Barcelona, Spain. For details of the […]
GigaGen Announces $1.5M NIH Grant Award for Development of Recombinant Intravenous Immunoglobulin
GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has been awarded a $1.5 million Phase II grant from the National Institutes of Health (NIH). The Phase II grant was awarded through the NIH Small Business Innovation Research (SBIR) program in from the National Institute […]
GigaGen Announces Issue of US Patent for Polyclonal Antibody Production
GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is […]
GigaGen Highlighted in Biospace.com Story
GigaGen’s development of the world’s first synthetic immune system was covered recently in the Biospace.com story Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies. According to the article, “The development of therapeutics that harness the body’s immune system has exploded in popularity among biotech companies with many investing heavily in research and […]
GigaGen Announces Successful Completion of Technical Goals on Four NIH Grant Projects
GigaGen Inc., a world leader in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has achieved all of the technical goals for four Phase I grants from the National Institutes of Health (NIH). The Phase I grants were awarded through the NIH Small Business Innovation Research (SBIR) program in 2015 […]
GigaGen Highlighted in Genome Web
The potential of GigaGen’s single cell sequencing and expression platform to revolutionize immunotherapy drug development and target discovery was highlighted in the recent Genome Web story Expanding Single-Cell Technology, GigaGen Moves Forward in Drug Development Market. According to the article: “Single-cell analysis firm GigaGen has made a sharp turn in its business plans over […]